1 – 10 of 100
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer’s disease
(
- Contribution to journal › Article
- 2018
-
Mark
Cerebrospinal fluid biomarker levels: Total tau and phosphorylated tau as markers for rate of progression in Alzheimer’s disease.
2018) Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting 2018(
- Contribution to conference › Abstract
-
Mark
Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease
(
- Contribution to journal › Article
- 2017
-
Mark
The effect of white matter hyperintensities on statistical analysis of diffusion tensor imaging in cognitively healthy elderly and prodromal Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Preclinical effects of APOE ϵ4 on cerebrospinal fluid Aβ42 concentrations
(
- Contribution to journal › Article
-
Mark
Levels of cerebrospinal fluid biomarkers total tau and phosphorylated tau do not predict survival time after diagnosis of Alzheimer’s disease – An 18-year follow-up.
2017) 10th Clinical Trials Conference on Alzheimer’s Disease(
- Contribution to conference › Poster
-
Mark
No independent association between pulse wave velocity and dementia : a population-based, prospective study
(
- Contribution to journal › Article
- 2016
-
Mark
Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis.
(
- Contribution to journal › Article
-
Mark
CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios : better diagnostic markers of Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease
(
- Contribution to journal › Article